Review article: Pharmacological approaches for the treatment of thrombocytopenia in patients with chronic liver disease and hepatitis C infection

Alimentary Pharmacology and Therapeutics

Volumn 26, Issue SUPPL. 1, 2007, Pages 29-39

  Afdhal, N H ^a   McHutchison, J G ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AKR 501; AMG 531; ANTIBODY; CYTOKINE; ELTROMBOPAG; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GROWTH FACTOR; INTERLEUKIN 1; INTERLEUKIN 11; INTERLEUKIN 3; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; PLACEBO; PROMEGAPOIETIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT INTERLEUKIN 11; RECOMBINANT MEGAKARYOCYTE GROWTH AND DEVELOPMENT FACTOR; RECOMBINANT PROTEIN; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; THROMBOPOIETIN; UNCLASSIFIED DRUG;

CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DIARRHEA; DRUG INDUCED HEADACHE; DRUG TARGETING; EDEMA; FLUID RETENTION; HEART ARRHYTHMIA; HEPATITIS C; HUMAN; MEGAKARYOBLAST; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SYNCOPE; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS;

ANTIVIRAL AGENTS; CHRONIC DISEASE; CYTOKINES; HEMATINICS; HEPATITIS C; HUMANS; LIVER DISEASES; PATIENT CARE MANAGEMENT; RECEPTORS, THROMBOPOIETIN; THROMBOCYTOPENIA;

EID: 35448937502     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2007.03511.x     Document Type: Review

References (78)

1. Peck-Radosavljevic M. Thrombocytopenia in liver disease. Can J Gastroenterol 2000 14 (Suppl. D 60D 6D.
2. Bashour FN, Teran C, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with nonalcoholic chronic liver disease. Am J Gastroenterol 2000 95 : 2936 9.
3. Dienstag JL, McHutchison JG American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006 130 : 231 64 quiz 14-7.
4. Ong JP, Younossi ZM. Managing the hematologic side effects of antiviral therapy for chronic hepatitis C: anemia, neutropenia, and thrombocytopenia. Cleve Clin J Med 2004 71 (Suppl. 3 S17 21.
5. McCullough J. Current issues with platelet transfusion in patients with cancer. Semin Hematol 2000 2 (Suppl. 4 3 10.
6. Demetri GD. Targeted approaches for the treatment of thrombocytopenia. Oncologist 2001 6 (Suppl. 5 15 23.
7. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest 2005 115 : 3339 47.
8. Matsumura I, Kanakura Y. Molecular control of megakaryopoiesis and thrombopoiesis. Int J Hematol 2002 75 : 473 83.
9. Broudy VC, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood 1995 85 : 1719 26.
10. Teramura M, Kobayashi S, Hoshino S, Oshimi K, Mizoguchi H. Interleukin-11 enhances human megakaryocytopoiesis in vitro. Blood 1992 79 : 327 31.
11. Gurney AL, Carver-Moore K, de Sauvage FJ, Moore MW. Thrombocytopenia in c-mpl-deficient mice. Science 1994 265 : 1445 7.
12. de Sauvage FJ, Carver-Moore K, Luoh SM, et al. Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin. J Exp Med 1996 183 : 651 6.
13. Lok S, Kaushansky K, Holly RD, et al. Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature 1994 369 : 565 8.
14. Kaushansky K, Lok S, Holly RD, et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature 1994 369 : 568 71.
15. Farese AM, Hunt P, Boone T, MacVittie TJ. Recombinant human megakaryocyte growth and development factor stimulates thrombocytopoiesis in normal nonhuman primates. Blood 1995 86 : 54 9.
16. Bartley TD, Bogenberger J, Hunt P, et al. Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl. Cell 1994 77 : 1117 24.
17. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002 100 : 3457 69.
18. Kaushansky K, Broudy VC, Lin N, et al. Thrombopoietin, the Mp1 ligand, is essential for full megakaryocyte development. Proc Natl Acad Sci U S A 1995 92 : 3234 8.
19. Souyri M, Vigon I, Penciolelli JF, Heard JM, Tambourin P, Wendling F. A putative truncated cytokine receptor gene transduced by the myeloproliferative leukemia virus immortalizes hematopoietic progenitors. Cell 1990 63 : 1137 47.
20. Hunt P, Li YS, Nichol JL, et al. Purification and biologic characterization of plasma-derived megakaryocyte growth and development factor. Blood 1995 86 : 540 7.
21. Linden HM, Kaushansky K. The glycan domain of thrombopoietin enhances its secretion. Biochemistry 2000 39 : 3044 51.
22. Muto T, Feese MD, Shimada Y, et al. Functional analysis of the C-terminal region of recombinant human thrombopoietin. C-terminal region of thrombopoietin is a "shuttle" peptide to help secretion. J Biol Chem 2000 275 : 12090 4.
23. Nagahisa H, Nagata Y, Ohnuki T, et al. Bone marrow stromal cells produce thrombopoietin and stimulate megakaryocyte growth and maturation but suppress proplatelet formation. Blood 1996 87 : 1309 16.
24. Sungaran R, Markovic B, Chong BH. Localization and regulation of thrombopoietin mRNA expression in human kidney, liver, bone marrow, and spleen using in situ hybridization. Blood 1997 89 : 101 7.
25. Fielder PJ, Gurney AL, Stefanich E, et al. Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets. Blood 1996 87 : 2154 61.
26. Stefanich E, Senn T, Widmer R, Fratino C, Keller GA, Fielder PJ. Metabolism of thrombopoietin (TPO) in vivo: determination of the binding dynamics for TPO in mice. Blood 1997 89 : 4063 70.
27. Stoffel R, Wiestner A, Skoda RC. Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets. Blood 1996 87 : 567 73.
28. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood 1995 85 : 2720 30.
29. Kuter DJ, Beeler DL, Rosenberg RD. The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production. Proc Natl Acad Sci U S A 1994 91 : 11104 8.
30. Kuter DJ, Rosenberg RD. Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit. Blood 1994 84 : 1464 72.
31. Murone M, Carpenter DA, de Sauvage FJ. Hematopoietic deficiencies in c-mpl and TPO knockout mice. Stem Cells 1998 16 : 1 6.
32. Feese MD, Tamada T, Kato Y, et al. Structure of the receptor-binding domain of human thrombopoietin determined by complexation with a neutralizing antibody fragment. Proc Natl Acad Sci U S A 2004 101 : 1816 21.
33. Alexander WS, Metcalf D, Dunn AR. Point mutations within a dimer interface homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity. EMBO J 1995 14 : 5569 78.
34. Sabath DF, Kaushansky K, Broudy VC. Deletion of the extracellular membrane-distal cytokine receptor homology module of Mpl results in constitutive cell growth and loss of thrombopoietin binding. Blood 1999 94 : 365 7.
35. Drachman JG, Miyakawa Y, Luthi JN, et al. Studies with chimeric Mpl/JAK2 receptors indicate that both JAK2 and the membrane-proximal domain of Mpl are required for cellular proliferation. J Biol Chem 2002 277 : 23544 53.
36. Fishley B, Alexander WS. Thrombopoietin signalling in physiology and disease. Growth Factors 2004 22 : 151 5.
37. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002 13 : 61 73.
38. Rojnuckarin P, Drachman JG, Kaushansky K. Thrombopoietin-induced activation of the mitogen-activated protein kinase (MAPK) pathway in normal megakaryocytes: role in endomitosis. Blood 1999 94 : 1273 82.
39. Vadhan-Raj S, Murray LJ, Bueso-Ramos C, et al. Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer. Ann Intern Med 1997 126 : 673 81.
40. O'Malley CJ, Rasko JE, Basser RL, et al. Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation. Blood 1996 88 : 3288 98.
41. Harker LA, Roskos LK, Marzec UM, et al. Effects of megakaryocyte growth and development factor on platelet production, platelet life span, and platelet function in healthy human volunteers. Blood 2000 95 : 2514 22.
42. Kuter DJ, Goodnough LT, Romo J, et al. Thrombopoietin therapy increases platelet yields in healthy platelet donors. Blood 2001 98 : 1339 45.
43. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001 98 : 3241 8.
44. Basser RL, O'Flaherty E, Green M, et al. Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 2002 99 : 2599 602.
45. Schuster MW, Beveridge R, Frei-Lahr D, et al. The effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) on platelet recovery in breast cancer patients undergoing autologous bone marrow transplantation. Exp Hematol 2002 30 : 1044 50.
46. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000 95 : 2530 5.
47. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999 94 : 3694 701.
48. Fanucchi M, Glaspy J, Crawford J, et al. Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. N Engl J Med 1997 336 : 404 9.
49. Basser RL, Rasko JE, Clarke K, et al. Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. Blood 1997 89 : 3118 28.
50. Basser RL, Underhill C, Davis I, et al. Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer. J Clin Oncol 2000 18 : 2852 61.
51. Kuter DJ. New thrombopoietic growth factors. Blood 2007 109 : 4606 16.
52. Farese AM, Smith WG, Giri JG, Siegel N, McKearn JP, MacVittie TJ. Promegapoietin-1a, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. Stem Cells 2001 19 : 329 38.
53. Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep 2005 4 : 137 44.
54. Weich NS, Wang A, Fitzgerald M, et al. Recombinant human interleukin-11 directly promotes megakaryocytopoiesis in vitro. Blood 1997 90 : 3893 902.
55. Neben TY, Loebelenz J, Hayes L, et al. Recombinant human interleukin-11 stimulates megakaryocytopoiesis and increases peripheral platelets in normal and splenectomized mice. Blood 1993 81 : 901 8.
56. Schlerman FJ, Bree AG, Kaviani MD, et al. Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates. Stem Cells 1996 14 : 517 32.
57. Goldman SJ. Preclinical biology of interleukin 11: a multifunctional hematopoietic cytokine with potent thrombopoietic activity. Stem Cells 1995 13 : 462 71.
58. Leonard JP, Neben TY, Kozitza MK, Quinto CM, Goldman SJ. Constant subcutaneous infusion of rhIL-11 in mice: efficient delivery enhances biological activity. Exp Hematol 1996 24 : 270 6.
59. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996 87 : 3615 24.
60. Isaacs C, Robert NJ, Bailey FA, et al. Randomized placebo-controlled study of recombinant human interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with breast cancer receiving dose-intensive cyclophosphamide and doxorubicin. J Clin Oncol 1997 15 : 3368 77.
61. Artz AS, Ershler WB, Rustgi V. Interleukin-11 for thrombocytopenia associated with hepatitis C. J Clin Gastroenterol 2001 33 : 425 6.
62. Orazi A, Cooper RJ, Tong J, et al. Effects of recombinant human interleukin-11 (Neumega rhIL-11 growth factor) on megakaryocytopoiesis in human bone marrow. Exp Hematol 1996 24 : 1289 97.
63. Erickson-Miller CL, Delorme E, Giampa L, et al. Biological activity and selectivity for Tpo receptor of the orally bioavailable, small molecule Tpo receptor agonist, SB-497115. Blood 2004 104 : 2912a.
64. Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood 2004 104 : 3888a.
65. Erickson-Miller CL, Delorme E, Iskander M, et al. Species specificity and receptor domain interaction of a small molecule TPO receptor agonist. Blood 2004 104 : 2909a.
66. Bussel JB, Saleh M, Provan D, et al. Eltrombopag, a novel, oral platelet growth factor, increases platelet counts in thrombocytopenic patients and healthy subjects. J Clin Oncol 2006 24 (Suppl. 18 8602a.
67. Jenkins JM, Williams D, Deng Y, et al. Phase I clinical study of eltrombopag, an oral, non-peptide thrombopoietin receptor agonist. Blood 2007 109 : 4739 41.
68. Dusheiko GM, McHutchison JG, Afdhal NH, et al. Eltrombopag Maintains Platelet Counts During Myelosuppressive Pegylated Interferon Alpha Treatment of Chronic Hepatitis C Virus Infection [Abstract]. Presented at Digestive Disease Week, 19-24 May 2007, Washington, DC T1044).
69. Bussel JB, Cheng G, Saleh M, et al. Analysis of Bleeding in Patients with Immune Thrombocytopenic Purpura (ITP): A Randomized, Double-Blind, Placebo-Controlled Trial of Eltrombopag, an Oral Platelet Growth Factor [Abstract]. Presented at the American Society of Hematology 48th Annual Meeting and Exposition, 9-12 December 2006, Orlando, FL 475).
70. Suzuki K, Abe M, Fukushima-Shintani M, et al. YM477, a novel orally-active thrombopoietin receptor agonist. Blood 2005 104 : 2298a.
71. Desjardins RE, Tempel DL, Lucek R, Kuter DJ. Single and multiple oral doses of AKR-501 (YM477) increase the platelet count in healthy volunteers. Blood 2006 108 : 477a.
72. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004 25 : 52 60.
73. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004 76 : 628 38.
74. Bussel JB, Kuter DJ, George JN, et al. AMG 531, a thrombopoiesis- stimulating protein, for chronic ITP. N Engl J Med 2006 355 : 1672 81.
75. Kuter DJ, Bussel JB, George JN, et al. Long-term dosing of AMG-531 in thrombocytopenic patients of immune thrombocytopenic purpura: 48-week update. Blood 2006 108 : 476a.
76. Cerneus D, Brown K, Harris R, et al. Stimulation of platelet production in healthy volunteers by a novel pegylated peptide-based thrombopoietin (TPO) receptor agonist. Blood 2005 106 : 1249a.
77. Orita T, Tsunoda H, Yabuta N, et al. A novel therapeutic approach for thrombocytopenia by minibody agonist of the thrombopoietin receptor. Blood 2005 105 : 562 6.
78. Kai M, Motoki K, Yoshida H, et al. Domain subclass conversion improved activity of anti-Mpl agonist antibodies in the form of whole IgG. Blood 2006 108 : 1134a.